Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
57 hedge funds and large institutions have $104M invested in Adverum Biotechnologies in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 23 reducing their positions, and 6 closing their positions.
132% more capital invested
Capital invested by funds: $45M → $104M (+$59.4M)
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
4% more funds holding
Funds holding: 55 → 57 (+2)
0.24% more ownership
Funds ownership: 6.29% → 6.53% (+0.24%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
48% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$5.26M |
| 2 |
VA
VR Adviser
New York
|
+$4.09M |
| 3 |
AI
Acuitas Investments
Seattle,
Washington
|
+$645K |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$336K |
| 5 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$298K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$2.01M |
| 2 |
JP Morgan Chase
New York
|
-$1.27M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$796K |
| 4 |
BlackRock
New York
|
-$667K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$603K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
JP Morgan Chase
New York
| $2.9K | -$1.27M | -120,838 | -100% |
|
|
PA
52
Parallel Advisors
San Francisco,
California
| $1.59K | – | – | – |
|
53
Wells Fargo
San Francisco,
California
| $1.07K | +$32 | +3 | +5% |
|
|
BTI
54
Blue Trust Inc
Alpharetta,
Georgia
| $1K | – | – | – |
|
|
GIA
55
GHP Investment Advisors
Denver,
Colorado
| $378 | – | – | – |
|
|
AF
56
Allworth Financial
Folsom,
California
| $32 | – | – | – |
|
57
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $29 | – | – | – |
|
58
BNP Paribas Financial Markets
Paris,
France
| $5 | -$21 | -2 | Closed |
|
|
59
Assenagon Asset Management
Senningerberg,
Luxembourg
| – | -$603K | -84,065 | Closed |
|
|
CM
60
CM Management
Gulf Breeze,
Florida
| – | -$269K | -37,500 | Closed |
|
|
VF
61
Virtu Financial
New York
| – | -$10K | -1,450 | Closed |
|
62
Victory Capital Management
San Antonio,
Texas
| – | -$7.29K | -1,017 | Closed |
|
63
Citadel Advisors
Miami,
Florida
| – | -$3.03K | -422 | Closed |
|
ADVM Hedge Fund Activity: Q2 2023 in Review
57 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q2 2023, worth a combined $104M — up 132% from $45M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ADVM positions and 6 closed out — a net gain of 2 holders — while 12 added to existing stakes and 23 trimmed.
The largest buyer was Commodore Capital, adding an estimated $5.26M. The largest seller was BML Capital Management, cutting an estimated $2.01M.
- 57 institutional investors held Adverum Biotechnologies (ADVM) as of Q2 2023, up from 55 in Q1 2023.
- Funds reported $104M of Adverum Biotechnologies stock for Q2 2023, up 132% quarter-over-quarter.
- 8 funds opened new Adverum Biotechnologies positions in Q2 2023 and 6 closed out, a net change of +2 holders.
- The largest Adverum Biotechnologies buyer in Q2 2023 was Commodore Capital, an estimated $5.26M added.
- The largest Adverum Biotechnologies seller in Q2 2023 was BML Capital Management, an estimated $2.01M sold.
Based on aggregated 13F filings for Q2 2023.